Neumora Therapeutics, Inc. reported a net loss of $236.9 million for the year ended December 31, 2025, compared to a net loss of $243.8 million for the previous year. The company, a clinical-stage biopharmaceutical firm, has yet to generate revenue from product sales. Operating expenses totaled $241.2 million, which included research and development costs of $176.1 million, general and administrative expenses of $60.1 million, and acquired in-process research and development expenses of $5.0 million.
The company's financial performance saw some significant shifts compared to the prior fiscal year. Research and development expenses decreased by $24.9 million, primarily due to the completion of the KOASTAL-1 Phase 3 trial for navacaprant. This decrease was partially offset by increased spending on preclinical research, manufacturing, and clinical trial-related costs for the M4 PAM and NMRA-511 programs. General and administrative expenses also saw a slight decrease of $2.4 million, attributed to reduced consulting and personnel-related costs. Interest income decreased by $11.6 million due to lower balances in cash equivalents and marketable securities, while interest expense of $3.2 million was incurred due to the company's loan agreement.
Operationally, Neumora designated NMRA-898 as the lead program in its M4 franchise, citing promising clinical results from a Phase 1 single ascending dose study. The company is currently conducting a multiple ascending dose study with NMRA-898 in healthy volunteers and patients with stable schizophrenia, with data expected in the second half of 2026. In the first quarter of 2026, Neumora reported NMRA-511 Phase 1b results, demonstrating a clinically meaningful effect size in people with AD agitation. The company plans to report data from a multiple ascending dose expansion cohort evaluating higher doses of NMRA-511 in the second half of 2026 and to initiate a Phase 2 study with NMRA-511 in Alzheimer’s disease agitation in the first quarter of 2027.
Looking ahead, Neumora anticipates several key updates from its programs throughout 2026, including topline data from the Phase 3 KOASTAL-2 and -3 studies in the second quarter, and data from the multiple ascending dose study with NMRA-898 in the second half of the year. The company believes its existing cash and cash equivalents of $182.5 million as of December 31, 2025, will be sufficient to fund operating expenses and capital expenditure requirements through at least the next 12 months. However, the company expects to require substantial additional funding in the future to continue its development programs and commercialization efforts.
About Neumora Therapeutics, Inc.
Neumora Therapeutics is a clinical-stage biopharmaceutical company focused on developing innovative therapies for brain diseases. Its pipeline includes programs targeting neuropsychiatric and neurodegenerative disorders, such as depression, dementia-related agitation, schizophrenia, ALS, and Parkinson’s disease. The company leverages novel mechanisms, AI-driven precision neuroscience, and proprietary compounds to address unmet medical needs in mental health and neurodegeneration.
About 10-K Filings
A 10-K form is a comprehensive annual report that public companies in the United States must file with the SEC, providing a detailed overview of the company's financial condition, performance, and business strategies.
Key points about the 10-K:
- Frequency: Filed annually, typically within 60 to 90 days after the end of the company's fiscal year.
-
Content: It includes:
- Detailed financial statements audited by an independent accounting firm
- Management's Discussion and Analysis (MD&A) of financial condition and results
- Description of the company's business, properties, and legal proceedings
- Risk factors and market risks
- Executive compensation and corporate governance information
- Importance: Considered the most comprehensive and important document a public company files with the SEC.
- Length: Often exceeds 100 pages due to its extensive and detailed nature.
Our Methodology
AssetRoom is committed to providing timely summaries of news from public companies. We use AI to generate these summaries quickly, but they are not reviewed by human experts.
Our method:
- Data Collection: We continuously monitor for new filings (currently limited to US-listed stocks).
- AI-Powered Analysis: Our advanced AI system processes each filing, identifying key information and extracting relevant data.
- Summary Generation: The AI creates a concise, easy-to-understand summary of the filing, highlighting the most important points.
- Publication: The summary is immediately published on our platform, allowing users instant access to the latest information.
- Email users: We distribute round-up emails according to our users preferences, keeping them in the loop with the companies they follow.
Feedback & Corrections
Spot an error or have a suggestion? Contact us.